Sangamo BioSciences reported $356K in Sales Revenues for its fiscal quarter ending in June of 2024.





Sales Change Date
Alaunos Therapeutics USD 2K 2K Mar/2025
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Amgen USD 10.4B 300M Sep/2026
Bayer EUR 10.05B 820M Sep/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Biogen USD 2.8B 60M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Cipla INR 74.04B 2.85B Sep/2026
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 2.6M 3.75M Jun/2026
CSL USD 8.33B 4.79B Dec/2025
Gilead Sciences USD 8.3B 500M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Grifols EUR 2B 306.7M Mar/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
J&J USD 25.4B 89M Sep/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Merck USD 18.1B 1.5B Sep/2026
Novartis USD 14.52B 112M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 14.44B 2.49B Sep/2026
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026